9/13/2007 10:49:04 AM
NEW YORK & MINNEAPOLIS--(BUSINESS WIRE)--Mount Sinai School of Medicine (MSSM) and Medisyn Technologies today announced a collaboration for the development of novel ß-amyloid (Aß) lowering drugs as a treatment in Alzheimer’s disease. Starting with MSSM’s previous research data obtained from testing early-stage lead compounds, the collaboration utilizes Medisyn Technologies’ molecular topology Forward Engineering™ platform to build a diverse pipeline of Alzheimer’s disease drug candidates. The goal of the study is to complete in vivo efficacy validation of the novel drug candidates by the end of 2007.
comments powered by